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Symbols and abbreviations 
 
 ºC  degrees Celsius 
DCM dichloromethane 
TEA triethylamine   
THF tetrahydrofuran 
EWG electron withdrawing group 
EDG electron donating group 
EtOH ethanol  
mg milligram 
gHMBC gradient Heteronuclear Multiple Bond Correlation 
Temp temperature 
m.p. melting point  
d.p. decomposition point  
g  gram  
mol  mole  
mmol milli mole 
MS mass spectrometry  
IR infrared spectroscopy 
NMR nuclear magnetic resonance spectroscopy 
ppm part per million  
s singlet  
d doublet 














The aim for this project was to cyclize the chalcones derivatives in order to produce 
flavonoids. The starting materials were synthesized according to the procedure that was 

















Scheme 1. Synthetic rout for target flavonoids. 
 
This was achieved via halogenation of double bond and ring closing based on 
nucleophilic substitution. By changing the substituents Y on an aromatic ring of the starting 
material, the effect on bromination of the double bond and a formation of five or six member 
rings was studied. The reaction with chalcones without any substituent on the aromatic ring 
led to a formation of six member ring, meanwhile the chalcones with an electron withdrawing 
group led to a mixture of five and six member rings.  
However, during this project we faced with some difficulties in synthesizing particular 









1.1. Barbituric acid 
First barbituric acid (2,4,6-trioxohexahydropyrimidine) (Figure 1) was synthesized in 












Figure 1. The structure of barbituric acid. 
 
For almost a half of the century many derivatives were synthesized, but only early in 
the 20th century it was discovered that some barbituric acid derivatives have an effect on the 
central nervous system. During that period many derivatives of barbituric acid were used as 
drugs side-effects. 
One of the ways of making potentially biologically active compounds is modification 
on C-5 of barbituric acid (Figure 1). Combination of barbituric acid moiety with other 
pharmacophoric groups gives possibility to synthesized numerous derivatives with potential 
biological effect. 
Figure 2 displays barbituric acid derivatives which were tested for biological activity 
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Chalcones are the products of the condensation of a simple or substituted aromatic 
moiety with a simple or substituted acetophenone in presence of base. This group of 





Figure 3. Structure of chalcones. 
 
 Gorovoy[6], Guyader [7], reported a large number of chalconoids with different 
substituents, which were synthesized by using barbituric acid as starting compound (Figure 








Figure. 4 Structure of chalcone with barbituric acid moiety. 
 






















Figure 5. Chemical structures of 5-, 6- and 7- member ring heterocyclic compounds. 
 
These compounds were tested for kinase activities and results showed that some of 
them are slightly active, though have low water solubility.  
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Another biologically important class is flavonoids. Flavonoids can be synthesized by 







Figure 6. Structure of flavonoid. 
1.3. Flavonoids 
Flavonoids are commonly found in fruits, vegetables, nuts, seeds, stems, flowers, tea, 
wine, propolis and honey and very often used for medical reason to treat human diseases.  
There are 14 classes of flavonoids, which differ by the pattern of substitution of the B ring 
and the oxidation level. Though the compounds of the same group also differ by substitution 





Figure. 7 Basic structure of flavonoid. 
 
Flavonoids are compounds, that consist of 15 carbons atoms in three a simple or 
substituted rings (C6–C3–C6) or (C6–C2–C6) and carbonyl function on it. They can be 
subdivided in to several classes: flavones 5, flavanone 6, isoflavone 7, isoflavanone 8 and to 
















8 9 10  
Figure 8. Favonoids. 
 
In nature more often 6-member ring instead 5-member ring flavonoids can be found. 
But aurones are well studied too and some of them are potential inhibitors of Hepatitis C 
virus[9].  
In addition to the flavonoids that were displayed in a Figure 8, there are also polymeric 
derivatives, called tannins, which are divided into two groups depending on their structure, 
i.e. condensed and hydrolysable. As it can be seen from a Figure 9, condensed tannins are the 


















































Hydrolysable tannin Condensed tannin
 
Figure 9. Chemical structure of gallic acid, hydrolysable tannin and condensed tannin. 
 
An interest in flavonoids is increasing with every day when they are being discovered 
to be more and more significant for medical reasons. Many of isolated flavone possesses 
antifungal, antiviral and antibacterial, anticancer[10], cytotoxicity, anti – inflammatory[11, 12] 
and antitumor activities. Moreover, they have been used for chemotherapy treatments. They 
also showed the possibility to protect the human body from free radicals and act like an 
antioxidants[13]. Figure 9 introduce to the most widely used flavonoids, which can be divided 
into groups of flavonoids, like flavones (luteolin)[14], flavonol (quercetin)[15], flavanone 







































Figure 10. Chemical structures of most widely used flavonoids. 
 
1.3.1. Antimicrobial activity 
 
The fact that pathogens are becoming more resistant to the antimicrobial agents leads 
to a need for development of new therapeutic agents. Therefore flavonoids are becoming a 
very important subject of medical research. Already in ancient times they have been used for 
treatment of human diseases, for example Tagetes minuta plant[19] was used for infectious 
disease treatment according to argentian medicine. Flavonoids have been widely investigated 
and known for their antibacterial, antifungal and antiviral activities.   
1.3.2. Antibacterial activity 
 
Flavonoids exhibit direct and synergistic antibacterial activity and suppression of 
bacterial virulence factors, including enzymes, toxins and signal receptors[20].  Antibacterial 
activity can be displayed by six main classes of flavonoids, which are flavones, flavonols, 
chalcones, flavan-3-ols and flavolans.  
1.3.3. Antifungal activity 
 
Most of the flavonoids that exhibit antifungal activity are found in plants as 
isoflavonoids, flavans or flavanones. Having an ability to inhibit spore germination of plant 
pathogens they can be used in a human body too[21]. For the first time there was used chlorine 
containing flavonoid chlorflavonin which was specific for antifungal features and was found 
in Aspergillus candidus[22].  
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1.3.4. Antiviral activity 
 
There have been reported flavonoids that possess antiviral activity against 11 types of 
viruses[23]. It is known that flavones can act against Herpes simplex virus type 1[24]. Moreover 
flavonoids are widely investigated against human immunodeficiency virus (HIV), which is 
causative agent of AIDS. It have been tested that flavans are more active that flavones and 
flavonones in the inhibition of immunodeficiency viruses[25].  
1.3.5. Antioxidant activity 
 
One of the most attractive features of flavonoids is the possibility to act as an 
antioxidant.  During the metabolism processes in our body there are produced free radicals 
and reactive oxygen species (ROS), which continuously make damage for our organism. This 
oxidative damage can be a cause of some diseases as cataracts, cognitive dysfunction, cancer 
or heart disease[8]. Some of the flavonoids, like quercetin, kaempferol, morin, myricetin and 
rutin act as antioxidants and protect the body against ROS[26], by suppressing the formation of 
reactive oxygen species, by scavenging reactive oxygen species or by upregulating 
antioxidant defenses. 
1.3.6. Other biological activities 
 
In addition to the mentioned before flavonoids contain a large number of compounds 
which expose more than 30 types of biological and chemical activities. They are known for 
their antiulcer acitivity[27], hepatoprotective activity[28], anti – inflammatory[29], antidiabetic 
effects[30], effects on cardiovascular system[31], antiatherosclerotic[32], antithrombogenic[33], 
cardioprotective[34], antineoplastic activity[35],  effects of nervous systems[36] and many others. 
So, it suggests that the new ways for the synthesis of the flavonoids need to be discovered and 
investigated. 
There are many ways for synthesis of new useful flavonoids. One of the possibility for 
flavonoids synthesis from chalconoids can be 1, 4-addition.  
1.4. Cyclisation by 1, 4-addition 
“1, 4 - addition” is known as the Michael reaction. This is conjugated addition to a α, 
β-unsaturated carbonyl compounds. 
Like in intermolecular, the intramolecular Michael reaction involves the addition of a 
nucleophile, also called a ‘Michael donor’, to an acceptor the ‘Michael acceptor’, usually of 
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Scheme 2. Scheme for Michael reaction. 
 
The intramolecular Michael reaction most often leads to the formation of a ring, either 
carbo- or heterocyclic. 
There are basically two ways to promote the reactivity. 
One way is to make nucleophile more negative. It can be done by using base as a 
catalyst, like tertiary amines or hydroxides. But strong base can lead an unwanted result, like 
destruction of molecule. 
 Another way is to increase electrophility of β-unsaturated carbon. For that reason  it 
can be used Lewis-acid[37] such as boron trifluoride, aluminum trichlorideor or zinc chloride. 
In this case Lewis acid coordinates to the carbonyl of the acrylate to activate an olefin. To 






2. The Aim  
The aim of the project was the cyclization of chalcones derivatives that were based on 
barbituric acid compounds, which have been mentioned before (Scheme 1).  
The cyclisation product is a compound that contains aromatic heterocyclic skeleton 







Figure. 11 Structure of flavone. 




3 Results and discussion 
3.1 Intramolecular cyclisation by conjugate addition of chalcones 1 
3.1.1. Thermal ring closing 
Intramolecular ring closing of compound 11 should be possible to make by using: 
microwave irradiation, ultrasound or heating[38]. The proposed mechanism for the synthesis 















Scheme 3.  Proposed mechanism for thermal ring closing . 
Compound 11 was dissolved in DCM (dichloromethane) and heated by microwave 
irradiation from five minutes till one hour in temperature range between 25-35 ºC. 
Temperature depended on the solvent boiling point, i.e. benzene 80 ºC, tetrahydrofuran 66 
ºC. Using microwave irradiation or ultrasound cyclization did not give successful result. 
Solid compound 11 decomposed when it was heated to 50-60 ºC above the melting 
point.   
3.1.2. Acid or base catalysed ring closing 
In order to ring close compound 11 conjugate addition catalyzed by acid or base as 
described in  literature[37, 39] was also studied. Suggested mechanism for acid as catalyst ring 
























Scheme 4. Acid catalysed ring closing. 
 
We used a wide range of acids like H2SO4, HCl, Dowex50, AcOH the reaction did 
not work. Microwave irradiation or heating with strong acid under reflux caused destruction 
of compound 11. 
A possible explanation for the difficulties with acid catalysed ring closing is that the 
keto-enol equilibrium of α,β-unsaturated ketones favors the keto structure, which is then less 
likely to cyclize (Scheme 5). Another explanation that arises, is that tautomers can be the 




















Scheme 5. Keto-enol equilibrium of α,β-unsaturated ketones. 
 
Reaction wit TEA (triethylamine), pyridine or piperidine as base did not give wanted 
result. 

























Scheme 6. Base catalysed ring closing. 
 
Problems with base catalyzed ring closing can be explained with not good enough 
electrophile side in the intermediate compound 16. 
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In the reaction with KOH as base in EtOH under reflux, instead of ring closing, 
precipitate of salt was obtained in a yield >90 % (Scheme 7). Using H2O instead of EtOH, 














Scheme 7. Reaction in ethanol. 
 
3.1.3. Lewis acid catalysed ring closing 
 
An interesting method for the synthesis of flavones, which was carried out under  
solvent free condition with silica gel supported InBr3[41]. The mechanism is shown in 































Using other Lewis acids such as CuCl2[42] or FeCl3 as catalyst for ring closing in  
THF (tetrahydrofuran) or DCM in room temperature or under reflux did not give wanted 
result.  
3.2 Intramolecular cyclisation by nucleophilic substitution 
3.2.1. I2 catalysed ring closing 
The first flavonoid that was successfully made from compound 11 was obtained 





























Scheme 9. Iodide catalysed ring closing. 
 
From compound 11 in DCM and catalytic amount of I2 under reflux for 17 hours 
compound 23 was obtained, unfortunately compound 23 was just a byproduct of the 
reaction. By changing time, temperature or solvent or amount of I2 only 1-8% yield was 
reached.  
Poor yield can be explainable by as described in Scheme 5. 
 
3.2.2. Halogenation of the double bond and ring closing 
In order to investigate the reactivity of the double bond of compound 11 bromination 
of the double bond was made. 
Reaction of the double bond was fast at room temperature in DCM and gave more 










Figure 12. Compound 26. 
 
Because of success cyclisation by using I2, it was decided to cyclize compound 26 via 
nucleophilic substitution[44]. 
In order to cyclize compound 26 it was heated to the melting point, at these 
conditions or refluxing in THF compound 26 lost both bromines and gave the unsaturated 
compound. Heat is not a common way for dehalogenation. Dehalogenation is usually done 
using Zn dust or NaI.   
Using slightly milder conditions, benzene and pyridine under reflux, a mixture of 
compounds 27 or 28 were obtained. The explanation for dehalogenation can be a very acidic 




























Scheme 10. Mechanism for dehydrohalogenation. 
 
Cyclisation of a compound 26 works well under reflux with TEA. From 1H NMR it 
was found out that the cyclized product contained TEA, which was not possible to remove 









































3.3. Cyclisation of compound 31 
The new starting material (compound 31) with electron donating group on aromatic 





















Figure 14. Compuond 32. 
 
Bromination of a double bond went very fast at room temperature in DCM or 
chloroform giving over 96% yield, but when it was left in chloroform under reflux for 18 











Figure 15. Compound 33 
 
To further investigate this reaction, p-methoxycinnamic acid (Figure 16) was reacted 
under the same conditions. This compound was chosen since it is the simplest commercial 
available compound that contains similar functional groups as compound 31. 
OH
O
MeO 34  




From the 1H NMR spectrum (Figure 17) can be seen, that the major compound after 
reaction is the tribromo compound. Doublet at 7.92 ppm, double doublet at 7.64 ppm and 
doublet at 7.09 ppm are protons from the aromatic ring on carbons 3, 4 and 6 of brominated 
compound. Two doublets from p-methoxycinnamic acid double bond moved from 7.75 ppm, 
6.33 ppm to 5.56 ppm and 5.37 ppm. This proves that it is possible to make bromination of 
double bond and electrophilic aromatic substitution under these conditions. 
 
Figure 17. 1H NMR spectrum. 
 
There are two possible mechanisms for obtaining the final product. The first possible 
mechanism can be explained as bromination of the double bond on compound 31. The second 
step can be spontaneous cyclisation that forms flavonoid 35. The final step could be 
bromination of double bond on compound 35 or 36 and addition of bromine on the aromatic 
ring. Final product can be the compound 37 or 38. This method is less likely because of the 















Figure 18. Compounds 35 and 36. 
 
The second possible mechanism for this reaction could be explained as bromination of 
a double bond 31 and cyclization followed by substitution of bromine on an aromatic ring. 
The second mechanism is more likely, because in separate steps it is possible to produce only 
bromination of double bond, but not substitution on aromatic ring. Non cyclized tri bromo 























Figure 19. Compounds 37 and 38. 
 
New compounds could be a five 38 or six 37 membered ring flavonoid. Because of the 
same molecular weight and similar 1H NMR or 13C NMR shifts it is difficult to tell which 
isomer is formed. To find out which ring had formed there was a need to run a gHMBC. This 
experiment allowed us to identify coupling between proton nuclei with carbon nuclei that are 
separated by more than one bond. From Figure 20 it can be seen that there is a correlation 
between a proton peak 6.2 ppm and carbon 68 ppm, 126 ppm, 131 ppm, 134 ppm, 168 ppm 
and 175 ppm peaks.  
Because of correlation between proton 6.2 ppm and two carbons that are two or three 




Figure 20 gHMBC correlations between proton and carbon 
 
Compound 31 behaved the same way as compound 11 under the same conditions 
















3.4. Cyclisation of the compound 40 
 
Because of unexpected results with electron donating group on aromatic ring, it was 
decided to make a bromination of double bond and cyclization using compound 40 with 
electron withdrawing group on an aromatic ring as starting material. 
Bromination of the double bond of compound 40 did not take a place in DCM at room 
temperature or under reflux. It was possible only in chloroform under reflux for 17-18 hours. 









Figure 22.  Compound 40. 
 
Cyclisation (Scheme 12) was possible in benzene by using TEA as base, but after 
cyclisation it still contained TEA, which was not possible to remove by washing or heating. 
Ring closing with even better yield, up to 75%, was obtained by changing TEA to pyridine. 



















































Scheme 12. Mechanism for ring closing compound 41. 
 
From Scheme 12 it can be seen, that there is a possibility to form two isomers and 1H 
NMR experiment confirmed this theory. From Figure 23 can be seen two pairs of doublets. 
One pair of doublet 7.99 ppm and 7.64 ppm belongs to the aromatic ring of one of the isomers 
and 7.58 ppm and 7.92 ppm to another isomer. Amount of formed isomers are not equal, but it 




Figure 23. 1H NMR spectra of isomers 37 and 39. 
 
From the gHMBC NMR spectra (Figure 24) can be seen which the major isomer of 
the reaction was. The proton at 7.01 ppm which could be the proton on the double bond has a 
correlation with carbons at 98 ppm, 129 ppm, 168 ppm, 171 ppm. Correlation between a 
proton of a double bond with only one carbon atom of an aromatic ring suggests that the 






Figure 24.  gHMBC NMR spectrum. 
  
Because of bad solubility it was difficult to obtain good spectra, so these two 
structural isomers were difficult to distinguish.   
The control of five or six membered ring formation was not successful. Changing 
solvent or temperature mostly affected the yield, but not which compound was formed.  
3.5. Cyclisation of compound 46 
In order to investigate all main substitution variations the last compound that was 








Figure 25. Compound 46. 
 
Bromination was possible only in chloroform under reflux for 17-18 hours and the 
yield of brominated compound was 75-85%.   
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Figure 26. Target compounds 47 and 48. 
 
1H NMR spectrum (Figure 27) of target compounds 47 and 48 showed that the isomers 
exist in a ratio about 1:1. It means that nucleophilic substitution occurs almost equally on both 
electrophilic sides. 
 
Figure 27.  1H NMR spectra of 47 and 48 isomers. 
 
Attempts to regulate the electrophilicity by changing temperature, base or solvents was 
not successful. 
In general for all chalcones, which were tried to cyclize 11, 31, 40, 46, the substituent 
on the aromatic ring had greatest effect for double bond halogenation. Electron density was 
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changing in all conjugated chains, depending what kind of substituent Y (EWG or EDG) was 









Figure 28. Chemical structure of starting chalcones. 
 
From data in a Table 1 can be seen how substituent on the aromatic ring affect the 
yield of bromination of double bond. The results vary from very fast bromination at room 
temperature or even ring closing at high temperature of compounds with an electron donating 
group to a very slow and only in high temperature bromination of the compounds with an 




























Figure 29. Compound 3 bromination products. 
 










Room temp. Reflux Room temp. Reflux 
Product Yield Product Yield Product Yield Product Yield 
-H XII >96% XII >96% XII >96% XII >96% 


















Depending on substituent (EWG or EDG) nucleophilic substitution can occur by 
pathway a or b. (Scheme 13) If the reaction goes according to pathway a, it forms a five 
membered ring, if by pathway b, six membered ring. That suggests that substituent Y on the 
aromatic ring has an influence on the electrophility of a compound and it has an also effect on 





















Scheme 13. Principal scheme of nucleophile attack place. 
 
 
As it can be seen from Table 2, it is hard or even impossible to make cyclization with 
electron donating group and the yields are higher it using an electron withdrawing groups as a 














































Product Yield Product Yield 
-H XI 40% XII 65-75% 
-OMe XII 30% XII 60-71% 
-Cl X and XI 45-70% X and XI 75% 
-NO2 X and XI 45-70%  X and XI 70-81% 
 
From Table 3 can be seen how substituents on the aromatic ring affect five or six 
membered ring formation. Reactions with unsubstituted aromatic ring led to six membered 
ring formation. With strong electron withdrawing group more five membered ring was 
formed. Five membered ring formation with electron donating group was an exception, 
because ring closing was following a different mechanism and under different conditions.  
 
Table 3. Ratio of 5/6 membered ring formation. 
 
 Substitution on the aromatic ring 
 -OMe -H -Cl -NO2 
5 membered ring 100% - 20% 50% 










4. Conclusions and future outlook 
 
Reactivity of double bond of chalconoids was investigated in bromination on double 
bond with different substituents on aromatic ring. In addition to that, the conditions for 
cyclisation for chalconoids were examined by changing the substituents on the aromatic ring 
of chalconoids.  
Fourteen new compounds were synthesized from chalcones and seven of them are 
flavonoids derivatives. 
 These methods for flavonoids synthesis offer several advantages including good yield, 
simple workup procedure, cheap chemicals and fast result. Only few steps were needed for 
the synthesis of new flavonoids. The reaction condition did not require any sophisticated 
equipment. 
Main disadvantage of this method was that it was difficult to control five or six 
member ring formation and in most of the cases, the result was a mixture of two isomers. 
Because of bad solubility these structural isomers were almost impossible to 
distinguish by NMR. It was also difficult to separate compounds. 
One of the opportunities to control five or six member ring formation can be different 
mechanism or conditions for ring closing. 
If would be interesting to make triple bond from double bond.  For the future outlook 








5. Experimental section 
Solvent and reagents were purchased form Sigma-Aldrich, Fluka, Aesar, Kenetyl, 
SAFC and Merck. All reagents and solvents were used without further purification. Reactions 
were monitored by 1H NMR spectra or silica gel plate 60 F 254. 
All new compounds were identified by: 1H NMR and 13C NMR spectra were recorded 
by a Varian Mercury400 plus (399.65/100.54 Mhz) at room temperature. Noteworthy data 
was reported in chemical shifts (δ) in part per million (ppm), relative to TMS (δ = 0.000 ppm) 
as an internal standard. Coupling constant (J) was measured Hertz (Hz). Multiplicity was 
reported in following order: s, singlet, d, doublet; dd, double doublet; t, triplet; m, multiplet). 
IR spectra were recorded on a Varian 7000e FT-IR spectrometer. Mass spectra were recorded 






5.1. Synthesis of starting materials 









Figure 31. Compound 49. 
 
Dimethylurea (7,5 g, 85 mmol; 1 eq) and malonic acid (9,7 g, 93 mmol; 1,1 eq) were 
mixed in an flask and acetic anhydride (16 ml) was added. The mixture slowly heated to 90 
ºC. When the exothermic reaction starts heating was stopped immediately, reaction 
temperature raised 130ºC. The solution was heated to 130ºC one more time and cooled to 
room temperature. Isopropanol was added to the solution causing a white precipitate to 
appear. The white precipitate was filtered and dried at room temperature. 
 











Figure 32. Compound 50. 
 
Compound 49 (15,25 g; 100 mmol; 1 eq) was suspended in a small amount of water 
and NaHCO3 (8,2 g; 100 mmol; 1 eq) was added as a concentrated water solution. The 
insoluble part was filtered off and acetic anhydride (18,48 ml; 200 mmol; 2 eq) was added to 
the stirred solution. The reaction mixture stirred was overnight and a white precipitate formed. 
Precipitate was filtered, washed with H2O and dissolved in 10% NH4OH. 3M HCl was added 
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to the solution until pH 7. The white precipitate was filtered off and washed with H2O and 
dried at room temperature. 
 










Figure 33. Chalconoids. 
 
5-acetyl-1,3-dimethybarbituric acid 1 eq. was mixed with 2 eq. of chosen  
benzaldehyde. The mixture was heated in an oil bath for two minutes kept at 170ºC. A 
catalytic amount of piperidine was added and the mixture was allowed to cool to room 
temperature. Ethanol was added to the solution and heated to boiling temperature. The 
solution was allowed to cool to room temperature. Precipitate filtered off and dried at room 
temperature. 
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Figure 34. Bromination of double bond of compound 11. 
 
Compound 11 (286 mg; 100 mmol, 1 eq) was dissolved in 4ml of dichloromethane. 
Bromine (103 mg; 200 mmol; 2 eq) was added to the solution. The mixture was stirred at 
room temperature for 20 minutes and the solvent was evaporated. 
 




1H NMR (400 MHz, Chloroform-d) δ 18.15 (s, 1H), 7.52 (dd, J = 8.0, 1.6 Hz, 2H), 7.46 – 
7.35 (m, 3H), 7.21 (d, J = 11.7 Hz, 1H), 5.53 (d, J = 11.7 Hz, 1H), 3.45 (s, 3H), 3.42 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 190.31, 170.19, 160.35, 149.68, 137.76, 129.44, 
128.92, 128.26, 94.28, 49.38, 46.45, 28.37. 
IR: 3048, 1728, 1659, 1505, 1451, 1367, 1335, 1277, 1222, 1145, 1058, 1007, 905, 843, 800, 





















Figure 35. Bromination of double bond of compound 31. 
 
Compound 31 (316 mg; 100 mmol, 1 eq) was dissolved in dichloromethane 6 ml. 
Bromine (103 mg; 200 mmol; 2 eq) was added to the solution. The mixture was stirred at 
room temperature for 20 minutes and the solvent was evaporated. 
High-resolution mass spectroscopy (ESI): (M+H)+ calculated 474.9426 for C16H17Br2N2O4 
found 474.9327 (80%).  
1H NMR (400 MHz, Chloroform-d) δ 18.12 (s, 1H), 7.44 (d, J = 8.7 Hz, 3H), 7.19 (dd, J = 
11.8, 1.0 Hz, 2H), 6.92 (d, J = 8.8 Hz, 3H), 5.54 (d, J = 11.7 Hz, 2H), 3.83 (s, 6H), 3.44 (s, 
6H), 3.41 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 190.38, 170.18, 160.32, 149.69, 129.67, 129.02, 
114.28, 94.24, 55.34, 49.83, 46.73, 28.32. 
IR: 3043, 2443, 2286, 1728, 1660, 1608, 1557, 1501, 1450, 1367, 1308, 1255, 1220, 1178, 


























Figure 36. Bromination of double bond of compound 40. 
 
Compound 40 (320 mg; 100 mmol, 1 eq) was dissolved in dichloromethane (4 ml). 
Bromine (103 mg; 200 mmol; 2 eq) was added to the solution. The mixture was heated under 
reflux for 17 hours and the solvent was evaporated. The solid product was purified by silica 
gel column chromatography (dichloromethane / EtOAc 5:1). 
 
High-resolution mass spectroscopy (ESI): (M+H)+ calculated 478.8931 for C15H13Br2ClN2O4 
found 478.8824 (100%),  
1H NMR (400 MHz, Chloroform-d) δ 18.13 (s, 1H), 7.44 (dd, J = 8.6, 1.8 Hz, 2H), 7.38 (dd, J 
= 8.6, 1.8 Hz, 2H), 7.14 (dd, J = 11.7, 1.7 Hz, 1H), 5.49 (d, J = 11.7, 1.9 Hz, 1H), 3.44 (d, J = 
1.7 Hz, 3H), 3.41 (d, J = 1.6 Hz, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 190.04, 170.18, 160.34, 149.61, 136.37, 135.28, 
130.61, 129.59, 129.17, 128.51, 94.25, 48.27, 46.23, 28.37. 



























Compound 46 (331 mg; 100 mmol, 1eq) was dissolved in dichloromethane (7 ml). 
Bromine (103 mg; 200 mmol; 2 eq) was added to the solution. The mixture was under reflux 
for 17 hours. The reaction was monitored by TLC and 1NMR. The solvent was evaporated. 
 
High-resolution mass spectroscopy (ESI): (M+Na)+ Calculated for C15H13Br2N3O6 513,9982, 
found 513,8912 (100%).  
1H NMR (400 MHz, Chloroform-d) δ 18.16 (s, 1H), 8.27 (dd, J = 8.8, 2.2 Hz, 2H), 7.68 (dd, J 
= 8.9, 2.2 Hz, 2H), 7.26 (d, J = 2.3 Hz, 0H), 7.16 (dd, J = 11.7, 2.3 Hz, 1H), 5.56 (dd, J = 
11.8, 2.2 Hz, 1H), 3.45 (d, J = 2.2 Hz, 3H), 3.41 (d, J = 2.3 Hz, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 189.59, 179.45, 179.08, 170.20, 160.32, 149.5, 148.20, 
144.71, 129.34, 124.17, 94.28, 76.68, 46.79, 45.63, 28.42. 
IR: 3040, 2454, 2286, 1728, 1659, 1567, 1523, 1444, 1375, 1200, 1198, 1654, 1005, 908, 860, 
830, 800, 756, 717, 695, 641 cm-1. 























Figure 38. Compuonds 32 and 39. 
 
Compound 32 (236mg, 1 eq, 0.5 mmol) was dissolved in benzene (5 ml). Pyridine (40 
mg, 1 eq, 0,5mmol) was added to solution and left for one hour under reflux.  Precipitate was 
filtered off and washed with benzene. The solid product 39 was left for drying at room 
temperature. 
 
High-resolution mass spectroscopy (ESI): (M+H)+ Calculated for C16H15BrN2O5 395.0164, 




1H NMR (400 MHz, Chloroform-d) δ 7.41 (d, J = 8.6 Hz, 2H), 7.04 – 6.94 (m, 2H), 5.91 (s, 
1H), 4.47 (s, 1H), 3.85 (s, 3H), 3.56 (s, 3H), 3.36 (s, 3H).. 
13C NMR (101 MHz, cdcl3) δ 172.73, 145.90, 141.04, 128.31, 127.44, 127.06, 114.21, 97.01, 
82.23, 77.31, 77.00, 76.68, 55.38, 50.72, 29.80, 28.14. 
IR: 3082, 1732, 1680, 1624, 1603, 1485, 1430, 1365, 1310, 1252, 1182, 1129, 1050, 1024, 
911, 840, 791, 748, 660 cm -1. 





















Figure 39. Ring closing of compound 30. 
 
Compound 30 (316mg; 100mmol, 1eq) was dissolved in chloroform (4ml). Bromine 
(103 mg; 200mmol; 2eq) was added to the solution and left for 17 hours under reflux.   
Precipitate was filtered and washed with chloroform and dried in room temperature. 
 
High-resolution mass spectroscopy (ESI): (M+Na)+ calculated 572,8319 for C16H13Br3ClN2O5 
found 572.8274 (50%). 
1H NMR (400 MHz, DMSO-d6) δ 7.91 (d, J = 2.2 Hz, 1H), 7.73 (dd, J = 8.6, 2.2 Hz, 1H), 
7.26 (d, J = 8.7 Hz, 1H), 6.14 (s, 1H), 3.92 (s, 3H), 3.31 (d, J = 2.9 Hz, 3H), 3.18 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 172.73, 145.90, 141.04, 128.31, 127.44, 127.06, 
114.21, 82.23, 76.68, 55.37, 50.72, 29.80, 28.14. 
IR: 3070, 2952, 2394, 2285, 1735, 1688, 1646, 1583, 1480, 1432, 1402, 1367, 1266, 1196, 























Compound 11 (284 mg; 100 mmol, 1 eq) was dissolved in 4ml of DCM. A catalytic 
amount of iodide (10 mg) was added to the solution and left for 17 hours under reflux and 
concentrated in vacuo. The solid product was purified by silica gel column chromatography 
(dichloromethane/ EtOAc 5:1)  
 
High-resolution mass spectroscopy (ESI): (M+H)+ calculated 285.0797 for C15H12N2O4 found 
258.0875 (100%). (M+Na)+ calculated 307.0689, found 307.0695 (9%). 
1H NMR (400 MHz, Chloroform-d) δ 7.72 (dd, J = 7.4, 2.3 Hz, 2H), 7.47 (dd, J = 5.2, 2.1 Hz, 
3H), 6.98 (s, 1H), 3.67 (s, 3H), 3.37 (s, 3H). 
13C NMR (101 MHz, cdcl3) δ 170.86, 133.48, 130.10, 130.00, 129.76, 128.49, 128.27, 40.63, 
40.40, 24.94. 
IR: 3086, 2924, 2737, 2675, 2432, 2260, 1720, 1675, 1618, 1582, 1530, 1485, 1459, 1429, 
























Compound 41 (318mg; 100mmol, 1eq) was dissolved in benzene (4ml). Pyridine 
(96mg; 120mmol; 1,2eq) was added to the solution and left for 17 hours under reflux. 
Precipitate was filtered and washed with benzene and dried at room temperature. The solid 
product was heated for 15 minutes at 110ºC.  
 
High-resolution mass spectroscopy (ESI): (M+H)+ calculated 319.7189 for C15H11ClN2O4 
found 319.0486  (20%). (M+Na)+ calculated 341.7087, found 341.0301 (30%), (M+K)+ 
calculated 357,8169, found 357.0040 (5%). 
1H NMR (400 MHz, DMSO-d6) δ 8.00 (7.94 – 7.88 (m, 2H), 7.64 (d, J = 8.6 Hz, 2H), 7.59 
(d, J = 8.6 Hz, 1H), 7.04 (s, 1H), 7.01 (s, 2H), 3.56 (s, 3H), 3.51 (s, 1H), 3.19 (s, 3H), 3.18 (s, 
1H). 
13C NMR (101 MHz, dmso) δ 174.57, 173.98, 161.86, 157.99, 149.76, 137.03, 133.44, 
129.79, 128.87, 128.22, 111.59, 104.99, 97.99, 30.03, 28.15. 























Compound 51 (329 mg; 100 mmol, 1 eq) was dissolved in benzene (5 ml). Pyridine 
(96 mg; 120 mmol; 1,2 eq) was added to the solution and left for 17 hours under reflux. 
Precipitate was filtered and washed with benzene and dried at room temperature. The solid 
product was heated for 15 minutes at 110ºC.  
 
High-resolution mass spectroscopy (ESI): (M+H)+ calculated 330.0773 for C15H11N4O5 found 
330.0719  (45%). (M+Na)+ calculated 351.9762, found 352.0534  (100%). 
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1H NMR (400 MHz, Chloroform-d) δ 8.41 (d, J = 8.9 Hz, 2H), 8.33 (d, J = 8.9 Hz, 2H), 7.92 
(d, J = 8.9 Hz, 2H), 7.89 (d, J = 8.9 Hz, 2H), 7.02 (s, 1H), 6.89 (s, 1H), 3.74 (s, 3H), 3.70 (s, 
3H), 3.43 (s, 3H), 3.40 (s, 3H). 
13C NMR (101 MHz, cdcl3) δ 131.67, 126.56, 124.67, 124.31, 111.49, 104.98, 76.44, 45.99, 
8.59. 
IR: 3744, 2422, 2254, 1717, 1676, 1622, 1586, 1497, 1430, 1407, 1302, 1194, 1129, 1091, 
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MS of 1,3-dimethyl-7-(4-nitrophenyl)-1H-pyrano[2,3-d]pyrimidine-2,4,5(3H)-trione and 
(Z)-1,3-dimethyl-6-(4-nitrobenzylidene)furo[2,3-d]pyrimidine-2,4,5(1H,3H,6H)-trione 
 
